EUVIMEDEUVIMED entdecken
Crossref

Discovery of a novel twin drug from Phillygenin and glucosamine for osteoarthritis treatment

Jiajing Zhang, Xinxin Lv, Yicong Sun, Jie Lu, Guangwei Cui, Guangfu Sun, Xiaobei Chen, Huan Xu, Yongqiang Zhang

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Jiajing Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, …. Hauptthemen laut MEDLINE: Glucosamine, Osteoarthritis, Drug Discovery, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The search for novel anti-OA agents that combine high efficacy with long-term safety remains a great challenge. Herein, we wish to disclose the distinct combined effect of TCM-derived lipophilic phillygenin and naturally-occurred hydrophilic glucosamine (GlcN) in OA treatment, which enables the subsequent design and syntheis of a series of twin drugs from these two OA therapeutic agents via the formation of glycosidic bond and further derivatization of amine group. Among them, twin drug 6 with an unsubstituted amine group and β-configuration exhibited the nost significant and dose-dependent in vivo anti-OA activity while no apparent toxicity was observed. In particular, it displayed comparable therapeutic efficacy and more favorable safety profiles compared to the clinically-used diacerein (DIA) and functions via multiple cellular mechanisms ranging from osteoclast differentiation inhibition and anti-inflammation/anti-oxidation to cartilage protection. Overall, our findings highlight 6 as a promising candidate for anti-OA drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosamineOsteoarthritisDrug DiscoveryAnti-Inflammatory Agents, Non-SteroidalAnimalsMolecular StructureStructure-Activity RelationshipHumansDose-Response Relationship, DrugMice

Stichwörter der Autor:innen

Combined effectDrug discoveryGlucosamineOsteoarthritisPhillygeninTwin drug

Substanzen

GlucosamineAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR C…
  • Shanghai GenSilicon Biotechnology Co., Ltd, Shanghai 201403, PR China.
  • School of Public Health, Anhui University of Science and Technology, Hefei, Anhui 231131, PR China. Electronic address: 2024078@aust.edu.cn.

Zitieren

APA

Zhang, J., Lv, X., Sun, Y., Lu, J., Cui, G., Sun, G., Chen, X., Xu, H., & Zhang, Y. (2026). Discovery of a novel twin drug from Phillygenin and glucosamine for osteoarthritis treatment. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110327

Vancouver

Zhang J, Lv X, Sun Y, Lu J, Cui G, Sun G, et al. Discovery of a novel twin drug from Phillygenin and glucosamine for osteoarthritis treatment. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110327

BibTeX
@article{Zhang2026,
  author = {Zhang, Jiajing and Lv, Xinxin and Sun, Yicong and Lu, Jie and Cui, Guangwei and Sun, Guangfu and Chen, Xiaobei and Xu, Huan and Zhang, Yongqiang},
  title = {Discovery of a novel twin drug from Phillygenin and glucosamine for osteoarthritis treatment},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110327}
}
Kostenlos starten →